Thomas E. D’Ambra, Ph.D. will retire as president and chief executive officer of Albany Molecular Research, Inc. (AMRI), effective December 31, 2013. Dr. D’Ambra will serve as the company’s non-executive chairman of the board at that time. William S. Marth, currently non-executive chairman of the AMRI board, will take over Dr. D’Ambra’s role, effective January 1, 2014. Mr. Marth will remain a member of the company’s board.
 
Mr. Marth brings global experience in strategic planning, investor relations, R&D, supply chain and regulatory. Mr. Marth joined AMRI’s board in June 2012. He formerly was president and chief executive officer of Teva Americas and also served as president and chief executive officer of Teva North America, president and chief executive officer of Teva USA, and executive vice president and vice president of sales and marketing for Teva USA.
 
Dr. D’Ambra, commented, “I am very proud of what AMRI has accomplished since my founding of the company over 22 years ago. We have achieved a track record of success in providing customers with a full range of high quality services together with informed decision-making, enhanced efficiency and more successful outcomes at all stages of the drug development process.
 
“I have been fortunate to have worked with a large number of current and former colleagues who have helped create and grow this wonderful organization and believe that market dynamics and the evolving business climate favor the continued growth of strategic outsourcing,” continued Dr. D’Ambra. “It is the right time for me to turn over the reins to a new leader and I am truly excited that Bill Marth will be leading the organization, particularly at this stage in the company’s evolution. Under Bill’s leadership I am confident the long term growth prospects for AMRI are bright and I look forward to working with and supporting Bill and the leadership team by re-assuming my role as Chairman.”
 
Kevin O’Connor, a director on AMRI’s board, commented, “On behalf of the AMRI board of directors, I’d like to thank Tom for his vision and leadership over the years. AMRI has demonstrated its adaptability as pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. Tom has been instrumental in successfully positioning AMRI as a leader in providing high quality outsourcing services to the industry, an area of focus that has tremendous promise in the future. Continuing their effective partnership, Tom will be working with Bill to ensure a seamless transition of day-to-day activities and we look forward to Tom re-assuming his role as chairman, as AMRI will continue to benefit from his vast industry expertise.”